• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by ProQR Therapeutics N.V.

    2/6/26 4:01:11 PM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRQR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)


    ProQR Therapeutics N.V.

    (Name of Issuer)


    Ordinary Shares, nominal value Euro 0.04 per share

    (Title of Class of Securities)


    N71542109

    (CUSIP Number)


    Van Herk Investments B.V.
    Lichtenauerlaan 30,,
    The Netherlands, P7, 3062 ME
    31-10-241-1555


    Evan S. Simpson
    1 New Fetter Lane,,
    London, X0, EC4A 1AN
    44 20 795984-26

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    02/05/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    N71542109


    1 Name of reporting person

    Van Herk Investments B.V.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    BK, WC, PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NETHERLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    15,384,250.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    15,384,250.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    15,384,250.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.6 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    * Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of ProQR Therapeutics N.V. (the "Issuer") issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    N71542109


    1 Name of reporting person

    Van Herk Investments THI B.V.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    BK, WC, PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NETHERLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,384,250.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,384,250.00
    11Aggregate amount beneficially owned by each reporting person

    15,384,250.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.6 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    * Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    N71542109


    1 Name of reporting person

    Van Herk Private Equity Investments B.V.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    BK, WC, PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NETHERLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,384,250.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,384,250.00
    11Aggregate amount beneficially owned by each reporting person

    15,384,250.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.6 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    * Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    N71542109


    1 Name of reporting person

    Stichting Administratiekantoor Penulata
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    BK, WC, PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NETHERLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,384,250.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,384,250.00
    11Aggregate amount beneficially owned by each reporting person

    15,384,250.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.6 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    * Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    N71542109


    1 Name of reporting person

    Van Herk Management Services B.V.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    BK, WC, PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NETHERLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,384,250.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,384,250.00
    11Aggregate amount beneficially owned by each reporting person

    15,384,250.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.6 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    * Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    N71542109


    1 Name of reporting person

    Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    BK, WC, PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NETHERLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,384,250.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,384,250.00
    11Aggregate amount beneficially owned by each reporting person

    15,384,250.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.6 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    * Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    N71542109


    1 Name of reporting person

    A. van Herk Holding B.V.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    BK, WC, PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NETHERLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,384,250.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,384,250.00
    11Aggregate amount beneficially owned by each reporting person

    15,384,250.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.6 %
    14Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:
    * Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    N71542109


    1 Name of reporting person

    Stichting Administratiekantoor Abchrys
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    BK, WC, PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NETHERLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,384,250.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,384,250.00
    11Aggregate amount beneficially owned by each reporting person

    15,384,250.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.6 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    * Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    CUSIP No.
    N71542109


    1 Name of reporting person

    Adrianus van Herk
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    BK, WC, PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    NETHERLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,384,250.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,384,250.00
    11Aggregate amount beneficially owned by each reporting person

    15,384,250.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    14.6 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    * Based on 105,345,192 ordinary shares, nominal value Euro 0.04 per share, of the Issuer issued and outstanding as of September 30, 2025, as reported in the Issuer's Form 6-K filed with the SEC on November 6, 2025.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Ordinary Shares, nominal value Euro 0.04 per share
    (b)Name of Issuer:

    ProQR Therapeutics N.V.
    (c)Address of Issuer's Principal Executive Offices:

    Zernikedreef 9, Leiden, NETHERLANDS , 2333 CK.
    Item 1 Comment:
    This Schedule 13D/A (this "Amendment No. 4") amends the Schedule 13D filed on May 28, 2025, as amended by Amendment No. 1 filed on August 20, 2025, Amendment No. 2 filed on September 4, 2025 and Amendment No. 3 filed on September 30, 2025 (collectively, the "Original Schedule 13D," and as amended and supplemented by this Amendment No. 4, the "Schedule 13D"). Except as amended hereby, the original disclosure set forth in the Original Schedule 13D shall remain unchanged. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Original Schedule 13D.
    Item 2.Identity and Background
    (a)
    The information previously provided in response to Item 2 is hereby amended and restated by replacing the text thereof in its entirety with the following: This statement is being filed by (i) Van Herk Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands ("VHI"), with respect to Ordinary Shares, nominal value Euro 0.04 per share (the "Ordinary Shares"), beneficially owned by it, (ii) Van Herk Investments THI B.V., a private company with limited liability incorporated under the laws of the Netherlands ("VHIT"), with respect to Ordinary Shares beneficially owned by VHI, (iii) Van Herk Private Equity Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands ("VHPI"), with respect to Ordinary Shares beneficially owned by VHI and VHIT, (iv) Stichting Administratiekantoor Penulata, a foundation organized under the laws of the Netherlands ("Penulata"), with respect to Ordinary Shares beneficially owned by VHI, VHIT and VHPI, (v) Van Herk Management Services B.V., a private company with limited liability incorporated under the laws of the Netherlands ("VHMS"), with respect to Ordinary Shares beneficially owned by VHI, VHIT and VHPI, (vi) Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V., a private company with limited liability incorporated under the laws of the Netherlands ("OGBBA"), with respect to Ordinary Shares beneficially owned by VHI, VHIT, VHPI and VHMS, (vii) A. van Herk Holding B.V., a private company with limited liability incorporated under the laws of the Netherlands ("Holdings"), with respect to Ordinary Shares beneficially owned by VHI, VHIT, VHPI, VHMS and OGBBA, (viii) Stichting Administratiekantoor Abchrys, a foundation organized under the laws of the Netherlands ("Abchrys"), with respect to Ordinary Shares beneficially owned by VHI, VHIT, VHPI, VHMS, OGBBA and Holdings, and (ix) Adrianus van Herk ("Mr. van Herk") with respect to Ordinary Shares beneficially owned by VHI, VHIT, VHPI, VHMS, OGBBA, Holdings, Penulata and Abchrys. Each of Mr. van Herk, VHIT, VHPI, Penulata, VHMS, OGBBA, Holdings and Abchrys disclaims beneficial ownership of the securities covered by this statement.
    (b)
    The principal business address of each of Mr. van Herk, VHI, VHIT, VHPI, Penulata, VHMS, OGBBA, Holdings and Abchrys is: Lichtenauerlaan 30 3062 ME Rotterdam The Netherlands
    (c)
    Mr. van Herk is (i) an investor, (ii) the holder of all of the depositary receipts issued by Penulata and Abchrys, (iii) the sole board member of Penulata and Abchrys, and (iv) the sole managing director of VHMS, OGBBA and Holdings. Penulata holds substantially all of the issued and outstanding shares of VHPI. VHPI is the sole shareholder of VHIT. VHIT is the sole shareholder of VHI. VHI is principally engaged in making investments. Abchrys holds substantially all of the issued and outstanding shares of Holdings. Holdings is the sole shareholder of OGBBA. OGBBA is the sole shareholder of VHMS and is principally engaged in making investments. VHMS is the sole managing director of VHI, VHIT and VHPI.
    (d)
    During the last five years, none of the Reporting Persons, nor, to the knowledge of the Reporting Persons, none of the executive officers or directors of the Reporting Persons, if applicable, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the last five years, none of the Reporting Persons, nor, to the knowledge of the Reporting Persons, none of the executive officers or directors of the Reporting Persons, if applicable, has been a party to a civil proceeding of a judicial or administrative body of a competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Each of VHI, VHIT, VHPI, VHMS, OGBBA and Holdings is a private company with limited liability incorporated under the laws of the Netherlands. Penulata and Abchrys are Netherlands foundations. Mr. van Herk is a citizen of the Netherlands.
    Item 3.Source and Amount of Funds or Other Consideration
     
    Item 3 of the Schedule 13D is amended by adding the following: From October 3, 2025 to February 5, 2026, VHI effected open market transactions in Ordinary Shares for its own account and ultimately acquired an aggregate of 1,054,560 Ordinary Shares for an aggregate net amount of $2,154,236.73. The sources of the funding for the purchase of Ordinary Shares were the general working capital of VHI.
    Item 4.Purpose of Transaction
     
    Item 4 of the Schedule 13D is amended by adding the following: The Reporting Persons acquired the Ordinary Shares reported herein for investment purposes in the ordinary course of business. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position and investment strategy, the price levels of the Ordinary Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, engaging in communications with management and the board of directors of the Issuer, engaging in discussions with stockholders of the Issuer or other third parties about the Issuer and the Reporting Persons' investment, including potential business combinations or dispositions involving the Issuer or certain of its businesses, making recommendations or proposals to the Issuer concerning changes to the capitalization, ownership structure, board structure (including board composition), potential business combinations or dispositions involving the Issuer or certain of its businesses, or suggestions for improving the Issuer's financial and/or operational performance, purchasing additional Ordinary Shares, selling some or all of their Ordinary Shares, engaging in short selling of or any hedging or similar transaction with respect to the Ordinary Shares, including swaps and other derivative instruments, or changing their intention with respect to any and all matters referred to in Item 4.
    Item 5.Interest in Securities of the Issuer
    (a)
    The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following: The information set forth in or incorporated by reference in Items 2, 3, 4 and 6 and on the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5.
    (b)
    The information set forth in or incorporated by reference in Items 2, 3, 4 and 6 and on the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5.
    (c)
    Except as set forth in this Schedule 13D, no transactions in Ordinary Shares of the Issuer have been effected during the past sixty days by any of the Reporting Persons.
    (d)
    Except as set forth herein, to the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any securities of the Issuer beneficially owned by the Reporting Persons as described in this Item 5.
    (e)
    Not applicable.
    Item 7.Material to be Filed as Exhibits.
     
    None.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Van Herk Investments B.V.
     
    Signature:/s/ Erik G.A. Esveld
    Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
    Date:02/06/2026
     
    Van Herk Investments THI B.V.
     
    Signature:/s/ Erik G.A. Esveld
    Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
    Date:02/06/2026
     
    Van Herk Private Equity Investments B.V.
     
    Signature:/s/ Erik G.A. Esveld
    Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
    Date:02/06/2026
     
    Stichting Administratiekantoor Penulata
     
    Signature:/s/ Erik G.A. Esveld
    Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
    Date:02/06/2026
     
    Van Herk Management Services B.V.
     
    Signature:/s/ Erik G.A. Esveld
    Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
    Date:02/06/2026
     
    Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.
     
    Signature:/s/ Erik G.A. Esveld
    Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
    Date:02/06/2026
     
    A. van Herk Holding B.V.
     
    Signature:/s/ Erik G.A. Esveld
    Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
    Date:02/06/2026
     
    Stichting Administratiekantoor Abchrys
     
    Signature:/s/ Erik G.A. Esveld
    Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
    Date:02/06/2026
     
    Adrianus van Herk
     
    Signature:/s/ Erik G.A. Esveld
    Name/Title:Erik G.A. Esveld/Attorney-In-Fact*
    Date:02/06/2026
    Comments accompanying signature:
    * Pursuant to a Power of Attorney, dated as of September 16, 2019, by and among the Reporting Persons.
    Get the next $PRQR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRQR

    DatePrice TargetRatingAnalyst
    4/29/2025$5.00Outperform
    Evercore ISI
    4/29/2025$8.00Overweight
    Cantor Fitzgerald
    3/10/2025$4.00Neutral → Buy
    Citigroup
    1/10/2025$15.00Outperform
    Oppenheimer
    10/29/2024$6.00 → $14.00Outperform → Strong Buy
    Raymond James
    11/8/2023$2.00Neutral → Buy
    Chardan Capital Markets
    3/30/2023$1.50 → $5.00Mkt Perform → Mkt Outperform
    JMP Securities
    12/22/2022$0.80 → $5.00Neutral → Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PRQR
    SEC Filings

    View All

    SEC Form 6-K filed by ProQR Therapeutics N.V.

    6-K - ProQR Therapeutics N.V. (0001612940) (Filer)

    2/9/26 8:07:21 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by ProQR Therapeutics N.V.

    SCHEDULE 13D/A - ProQR Therapeutics N.V. (0001612940) (Subject)

    2/6/26 4:01:11 PM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by ProQR Therapeutics N.V.

    6-K - ProQR Therapeutics N.V. (0001612940) (Filer)

    1/8/26 8:08:44 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRQR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on ProQR Therapeutics with a new price target

    Evercore ISI initiated coverage of ProQR Therapeutics with a rating of Outperform and set a new price target of $5.00

    4/29/25 8:12:03 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on ProQR Therapeutics with a new price target

    Cantor Fitzgerald resumed coverage of ProQR Therapeutics with a rating of Overweight and set a new price target of $8.00

    4/29/25 8:11:53 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Therapeutics upgraded by Citigroup with a new price target

    Citigroup upgraded ProQR Therapeutics from Neutral to Buy and set a new price target of $4.00

    3/10/25 7:58:48 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRQR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProQR Announces Planned Changes to Board Composition

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company's next Annual General Meeting (AGM) as their terms conclude.  The planned changes to ProQR's Board composition at its 2026 AGM reflect the Company's development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planni

    2/9/26 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook

    Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohortDevelopment Candidates selected for pipeline programs AX-2402 for Rett syndrome (MECP2, R270X) and AX-2911 for MASH (PNPLA3)Strategic collaboration with Eli Lilly achieved $4.5 million in milestones in 2025, contributing to strong financial position with runway into mid-2027 LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company d

    1/8/26 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR to Participate in 8th Annual Evercore Healthcare Conference

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 8:20am ET. Webcast details will be accessible from the "Investors & Media" section of ProQR's website (www.proqr.com) under "Events". Archived webcasts will be available for approximately 30 days following the presentation date. About Axiomer™ ProQR is pioneering a n

    12/1/25 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRQR
    Leadership Updates

    Live Leadership Updates

    View All

    ProQR Announces Planned Changes to Board Composition

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company's next Annual General Meeting (AGM) as their terms conclude.  The planned changes to ProQR's Board composition at its 2026 AGM reflect the Company's development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planni

    2/9/26 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth

    LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dennis Hom as Chief Financial Officer (CFO) and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer (CMO). These key leadership appointments support the advancement of the Company's Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage. "We are thrilled to welcome Dennis and Cristina to ProQR at such an important time in our evolution," said Daniel A

    4/14/25 7:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR's Scientific Advisory Board, where he has played an important role in shaping the Company's ADAR-based RNA editing platform. Dr. Beal's decades of res

    12/10/24 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRQR
    Financials

    Live finance-specific insights

    View All

    ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.  During the event, ProQR will highlight its proprietary Axiomer™ ADAR-mediated RNA editing platform, along with updates on its pipeline of development candidates including data updates and next steps on its programs for NTCP and B4GALT1, AX-0810 and AX-1412. Prese

    12/5/24 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases

    ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing OligonucleotidesPreclinical proof of concept for the Company's AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT Annual MeetingManagement webinar May 9, 2024 at 8:00 am EDT LEIDEN, Netherlands & CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced new preclinical data for its proprietary Axiomer™ RNA editing technology platform, incl

    5/8/24 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that ProQR management will host an investor conference call and webcast to discuss the Company's Axiomer RNA editing technology platform following the recently announced partnership expansion with Lilly. ProQR will host the call on December 22, 2022, at 8:15am EST.  The live and archived webcast of the presentation will be accessible through this webcast link, or to access the live call by phone please register here. A dial-in and unique PIN will be provided to join the call. The

    12/22/22 6:15:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRQR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

    SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)

    2/14/24 6:08:12 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ProQR Therapeutics N.V. (Amendment)

    SC 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)

    2/9/24 6:37:13 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ProQR Therapeutics N.V.

    SC 13G - ProQR Therapeutics N.V. (0001612940) (Subject)

    9/14/23 5:20:05 PM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care